Original Article

Outcomes of Idiopathic Pulmonary Fibrosis Improve with Obesity: A Rural Appalachian Experience

Authors: Rahul G. Sangani, MD, Andrew J. Ghio, MD, Hasan Mujahid, MD, Zalak Patel, MD, Kristen Catherman, MD, Sijin Wen PhD, John E. Parker, MD


Objectives: Obesity can be an independent predictor of fibrosis in tissues, including the liver, heart, and skin. We evaluated a rural Appalachian cohort of idiopathic pulmonary fibrosis (IPF) for its relation to obesity.

Methods: Using American Thoracic Society 2018 diagnostic guidelines, an IPF cohort was systematically identified at an Appalachian academic medical center (2015–2019). The cohort was categorized in subgroups of body mass index (BMI) <30 or BMI ≥30 kg/m2. Demographics, clinical variables, and treatment details were collected retrospectively and evaluated for their associations with obesity.

Results: In our IPF cohort (N = 138), a usual interstitial pneumonia pattern was less prevalent in the obese group (n = 49) relative to the nonobese group (69% vs 85%, respectively). The obese group was younger (mean age 73.27 ± 9.12 vs 77.97 ± 9.59 years) and had a higher prevalence of hypertension (90% vs 72%), hyperlipidemia (83% vs 68%), diabetes mellitus (47% vs 25%), sleep-disordered breathing (47% vs 25%), chronic pain disorders (28% vs 15%), and deep vein thrombosis (19% vs 7%). An increased proportion of obese-IPF patients was seen at a tertiary or an interstitial lung disease center, with more surgical lung biopsies performed and incident diagnosis (ie, within 6 months of presentation) assigned. Only a minority of patients underwent lung transplantation (3.6%), all of them from the obese-IPF subgroup. Approximately 30% of the total IPF cohort died, with a lower mortality observed in the obese group (35% vs 20%, P = 0.017). An increasing BMI predicted a better survival in the total IPF cohort (BMI 25–29.9, 20–24.9, and <20 had mortality rates of 20%, 47%, and 75%, respectively; P < 0.001).

Conclusions: Our study represents a first known effort to develop an IPF cohort in a rural Appalachian region. Although they shared an increased burden of comorbidities, the obese subgroup showed less advanced fibrosis with a lower mortality rate relative to nonobese subgroup, suggesting a potential “obesity paradox” in IPF. The study findings significantly advance our understanding of challenges posed by IPF in a rural population that also suffers from an alarming rate of obesity. We highlight the need for the multidisciplinary management of these patients and prospective studies to better define this complex relation.
Posted in: Pulmonary Disease14

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011;300:G697–G702.
2. Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res 2014;164:323–335.
3. Rutherford A, Glass DA 2nd. A case-control study analyzing the association of keloids with hypertension and obesity. Int J Dermatol 2017;56:e187–e189.
4. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198:e44–e68.
5. Salisbury ML, Tolle LB, Xia M, et al. Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respir Med 2017;131:229–235.
6. Snyder L, Neely ML, Hellkamp AS, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res 2019;20:105.
7. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007;117:524–529.
8. Sun K, Tordjman J, Clement K, et al. Fibrosis and adipose tissue dysfunction. Cell Metab 2013;18:470–477.
9. Gui X, Chen H, Cai H, et al. Leptin promotes pulmonary fibrosis development by inhibiting autophagy via PI3K/Akt/mTOR pathway. Biochem Biophys Res Commun 2018;498:660–666.
10. Hsu HS, Liu CC, Lin JH, et al. Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Sci Rep 2017;7:14272.
11. Park YH, Oh EY, Han H, et al. Insulin resistance mediates high-fat diet-induced pulmonary fibrosis and airway hyperresponsiveness through the TGF-beta1 pathway. Exp Mol Med 2019;51:1–12.
12. Adegunsoye A, Balachandran J. Inflammatory response mechanisms exacerbating hypoxemia in coexistent pulmonary fibrosis and sleep apnea. Mediators Inflamm 2015;2015:510105.
13. Alakhras M, Decker PA, Nadrous HF, et al. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 2007;131:1448–1453.
14. Jouneau S, Rousseau C, Lederlin M, et al. Low fat-free mass and body mass index are associated with worse survival in patients with idiopathic pulmonary fibrosis (IPF). Eur Resp J 2019;54(suppl 63):PA1337.
15. Mogulkoc N, Uysaler B, Bishop P. Does body mass index influence survival of patients with idiopathic pulmonary fibrosis? Eur Resp J 2018;52(suppl 62): PA2914.
16. Patel S, Nolan C, Barker R, et al. Body composition and mortality in idiopathic pulmonary fibrosis (IPF): a prospective cohort study. Eur Resp J 2018;52(suppl 62):PA2056.
17. Appalachian Research Council. Health disparities in Appalachia. https://www.arc.gov/report/health-disparities-in-appalachia/. Published August 23, 2017. Accessed August 30, 2020.
18. Albera C, Costabel U, Fagan EA, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 2016;48:843–851.
19. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968–1977.
20. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017;72:340–346.
21. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–381.
22. World Health Organization. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Published April 1, 2020. Accessed June 24, 2020.
23. Zammit C, Liddicoat H, Moonsie I, et al. Obesity and respiratory diseases. Int J Gen Med 2010;3:335–343.
24. Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Resp J 2017;49:1601592.
25. Alhamad EH. Clinical characteristics and survival in idiopathic pulmonary fibrosis and connective tissue disease-associated usual interstitial pneumonia. J Thorac Dis 2015;7:386–393.
26. Kelly BT, Moua T. Overlap of interstitial pneumonia with autoimmune features with undifferentiated connective tissue disease and contribution of UIP to mortality. Respirology 2018;23:600–605.
27. Migita K, Arai T, Jiuchi Y, et al. Predictors of mortality in patients with interstitial lung disease treated with corticosteroids: results from a cohort study. Medicine (Baltimore) 2014;93:e175.
28. Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:193–196.
29. Oldham JM, Noth I. Idiopathic pulmonary fibrosis: early detection and referral. Respir Med 2014;108:819–829.
30. Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med 2018;12:755–767.
31. Bernhardt V, Babb TG. Exertional dyspnoea in obesity. Eur Respir Rev 2016;25:487–495.
32. Sin DD, Jones RL, Man SF. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med 2002;162:1477–1481.
33. Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med 2017;5:161.
34. Gries CJ, Bhadriraju S, Edelman JD, et al. Obese patients with idiopathic pulmonary fibrosis have a higher 90-day mortality risk with bilateral lung transplantation. J Heart Lung Transplant 2015;34:241–246.
35. Lambert AA, Putcha N, Drummond MB, et al. Obesity is associated with increased morbidity in moderate to severe COPD. Chest 2017;151:68–77.
36. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–1012.
37. Courtney JM, Bradley J, McCaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007;42:525–532.
38. Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ 2016;353:i2156.
39. Elagizi A, Kachur S, Lavie CJ, et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis 2018;61:142–150.
40. Spelta F, Fratta Pasini AM, Cazzoletti L, et al. Body weight and mortality in COPD: focus on the obesity paradox. Eat Weight Disord 2018;23:15–22.
41. Papagianni M, Tziomalos K. Effects of obesity on the outcome of pneumonia. Expert Rev Endocrinol Metab 2017;12:315–320.
42. Zafrir B, Adir Y, Shehadeh W, et al. The association between obesity, mortality and filling pressures in pulmonary hypertension patients; the "obesity paradox". Respir Med 2013;107:139–146.
43. Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res 2017;113:1074–1086.
44. Culver DA, Behr J, Belperio JA, et al. Patient registries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2019;200:160–167.
45. Centers for Disease Control and Prevention. Behavioral risk factor data: tobacco use (2011 to present). https://chronicdata.cdc.gov/Survey-Data/Behavioral-Risk-Factor-Data-Tobacco-Use-2011-to-pr/wsas-xwh5. Accessed May 15, 2020.
46. Olson AL, Swigris JJ. Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin Chest Med 2012;33:41–50.
47. Baumgartner KB, Samet JM, Stidley CA, et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Me 1997;155:242–248.
48. Culver D, Yow E, Neely M, et al. Characteristics of patients with idiopathic pulmonary fibrosis (IPF) in the US: data from the IPF-PRO Registry. Chest 2018;154:397A–398A.
49. Guenther A, Krauss E, Tello S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res 2018;19:141.
50. Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J 2017;49:1601592.
51. Caminati A, Lonati C, Cassandro R, et al. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. Eur Respir Rev 2019;28:190044.